

USDM in Action: From Protocol to SDTM

Dave Iberson-Hurst Data4knowledge ApS





Meet the Speaker

Dave Iberson-Hurst

Title: Partner

Organization: data4knowledge ApS

40+ years' experience across several industries with the last 20 years spent in the pharmaceutical industry combining his technology and software development experience with clinical data standards. During this time, he has served as the CDISC CTO, worked on, and led, several CDISC teams, presented in many forums in Europe, the US, and elsewhere across the globe.

He has worked closely with the FDA, EMA, HL7, ISO, and other standards organizations and was was a member of CDISC's Blue Ribbon commission. He is currently the CDISC Product Owner for the Digital Data Flow project.

He is a partner at data4knoweldge in Copenhagen and is focused on getting greater value and utility from clinical trial data



Meet the Contributors

Kirsten Walther Langendorf

Title: Partner

Organization: data4knowledge ApS

20+ years' experience in the pharmaceutical industry within programming, IT implementation & validation, process improvement, CDISC standards implementation, and statistics.

As partner at data4knowledge in Copenhagen, she has been involved in implementing various e2e metadata driven systems based on linked data technologies.

Johannes Ulander

Title: Partner

Organization: data4knowledge ApS

20+ years' experience in standardizing clinical data and have been involved in implementing CDISC standards from an end-to-end perspective for the last 15 years. For the last 7 years by using linked data and graph databases.

He is a partner at data4knowledge in Umeå and an authorized CDISC SDTM instructor.



Disclaimer and Disclosures

- The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the official policy or position of CDISC.
- Contractor to CDISC as the DDF USDM Product Owner



Disclosure: It's All About Hats







This talk is about using the USDM as the foundation for much of what we do and the potential for the removal of silos and automation.

It is about the sharing of ideas.





Old Ideas Whose Time Has Come

- We [industry] have been looking at removing silos for a decade or more
- We have been looking at "eProtocol" for probably two decades or more
- DDF, USDM, ICH M11, precisonFDA ... all these initiatives / standards are making it a reality







Making better use of data



We help our customers make better use of their primary asset, the clinical data.

> Contact dih@data4knowledge.dk kwl@data4knowledge.dk

Overview

Over the past few years, the partners at d4k have worked on ways in which the handling of data can be improved, silos removed, and automation increased. But showing these ideas in action requires more than a few slides. To this end, we at d4k have built a demonstrator to illustrate the potential of using the Unified Study Definitions Model (USDM) with Biomedical Concepts (BCs) providing the foundation for the automation of downstream processes that industry has been lacking.

The demonstrator implements USDM version 3, CDISC Biomedical Concepts, CDISC Controlled Terminology, CDISC SDTM, and the emerging ICH M11 CeSHARP eProtocol standards to illustrate how the detailed study definition provides the foundation to link subject data to the study design thus allowing the automated generation of SDTM without the need for any programming. This same design can also be used for the generation of submission artefacts and this poster discusses how an implementation based upon the USDM can serve multiple purposes.

Key Takeaways:

- USDM is the foundation industry has been missing
- · USDM opens the door to multiple new innovations and approaches
- The TransCelerate end-to-end Digital Data Flow vision is achievable today

One Model: USDM at the Centre

Study Design

The technology demonstrator implements a single linked model. The heart of the model is provided by the USDM.

The USDM provides the ability to define the overall study design and logic and provides the foundation for everything that follows.

Study Detail



Biomedical Concepts are already linked into the USDM and provide the necessary detail and precision not normally found in existing, paper, protocols. BCs define the data to be collected and provide the basis for the data contract, the data needed to meet the study's needs

Operational Data

The USDM contains some site information but this is related to amendments and recruitment. This information is expanded to include more details needed to link subject data into the model.



Subject Data

We now have a full study definition to which subject data can be linked. This then creates a single linked graph containing both the study design plus the data; no more silos!

SDTM & Other Exports

We can now link SDTM to the data. The SDTM is linked to a small model (the CRM) that models the intricacies of observations. This model is also linked to the BCs (in fact BCs should be based on this model) such that there is a link from data to BC to SDTM. A similar approach can be taken with other data exports





Technology Demonstrator

The technology demonstrator implements the model described here and then populates it with data to show the concepts working.

We have leveraged the test data provided by the TransCelerate / CDISC DDF project taking the LZZT protocol and associated raw data and loading these data into a single model. From that we can automatically extract SDTM, aCRF and define.xml. Data capture instruments can also be driven from the metadata

Future work will look at such topics as subject and site burden, study risk and study cost.

> Scan the OR code to see a video of the demonstrator in action n . 19

Views

The expanded USDM model can serve many purposes. Many of the artefacts required within clinical development are simply extracts, exports or views, of one consistent and linked set of data.

Protocol: The entire protocol can be extracted, either in a sponsor template or the M11 template

Specific Views: Tailored views for specific roles, e.g. EDC build, data monitoring, can be accommodated.

EDC: Machine and human readable exports for EDC configuration.

CRF & Define: Data capture specifications. aCRFs and Define.xml can be generated from the model prior to a single data point being captured.

SDTM: As already noted the model supports the automated generation of SDTM datasets capable of supporting multiple versions of SDTMIG.

And many more: The expanded USDM model is not limited to the above exports or views. Many other use cases and exports could be envisaged such as subject journey, site risk, TMF and CTMS.

.....

......

........

.....



USDM as the Foundation

- 1. USDM is the foundation
- 2. Add the "data contract"
- 3. Attach subjects and their data
- 4. Link to SDTM





Technology Demonstrator DM Domain Data

- A Powerpoint just doesn't do the job
- Need to see the ideas in action
- Implemented in Python, FastAPI with a Neo4j database
- Has a basic User Interface (UI)
- We are continuing to work on it



cdisc

job	DOMAIN	USUBJID	SUBJID	RFXSTDTC	RFXENDTC	RFICDTC	DTHDTC	DTHFL	SITEID	INVID	INVNAM	Č.
- MC		702-1	02-1			2024-10- 18T09:12			702			1000
wit	ĥ	CDISC001	C001	2012-11- 30	2012-12- 13	2012-11- 23			701			
	DM	CDISC002	C002	2012-11- 15	2012-11- 28	2012-10- 30			701			100
	DM	CDISC003	C003	2013-08- 29	2013-09- 11	2013-08- 20			701			1000
	DM	CDISC004	C004	2013-10- 08	2013-10- 21	2013-10- 01			701			100
	ĎМ	CDISCODS	C005	2013-02- 04	2013-08- 04	2013-01- 22			701			1000
	DM	CDISC006	C006	2013-03- 19	2013-04- 01	2013-02- 25			701			100
	DM	CDISC007	C007	2013-01- 05	2013-01- 18	2012-12- 31			701			19
	DM.	CDISCOOR	C008	2014-05- 11	2014-05- 24	2014-05- 01			701			
	DM	CDISC009	C009		2013-04- 21				701			
1.44	init.	anisona.	Philip.	2012.00								2

2024 US CDISC+TMF Interchange | #Clear DataClear Impact



Paper to eProtocol using USDM

2. Objectives

2.1. Primary Objectives

The primary objectives of this study are

- · To determine if there is a statistically significant relationship (overall Type 1 error rate, α =.05) between the change in both ADAS-Cog (see Attachment LZZT.2) and CIBIC+ (see Attachment LZZT.3) scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).
- · To document the safety profile of the xanomeline TTS.

2.2. Secondary Objectives

the second second

cdisc

The secondary objectives of this study are

- · To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas (see Attachment LZZT.4).
- · To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will

Protocol Attachment LZZT.1 Schedule of Events for Protocol H2Q-MC-LZZT(c)

	VISIT	1	2	3	4	5	7	
ACTIVITY	WEEK	-2	3	0	2	4	6	
Informed consent		х						
Patient number assigned		Х						
Hachinski ≤4		Х						
MMSE 10-23		Х						
Physical examination		X						
Medical History		Х						
Habits		Х						
Chest x-ray		X						
Apo E genotyping					X			
Patient randomized				х				
Vital signs/Temperature		Х	Х	х	Х	Х	Х	
Ambulatory ECG placed			Х					
Ambulatory ECG removed				х				
ECG		х			Х	Х	Х	
Placebo TTS test		x						





The Detailed Design



Add in a "Data Contract"



Notes

- •The data contract is the set of data points needed to meet the needs of the study.
- Expands the SoA+ (e.g. observations repeated across visits)
- •The URI is the barcode for a single atomic data point, a unique identifier that persists forever.
- •Can be used for multiple purposes: external data providers, long term retention of data ...



4k Study Browser studies status

List of planned data points Note: BC Properties for study - select data collection:TRUE

Screening P2W

Chemistry

Rows:

Timeline

Main Timeline

Main

Timeline

Link the Subject Data

.....

USUBJID	C_URI	DATAPOINT_URI	VALUE
01-701-101	ttps://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/eed3c040- 518-42c9-bfcb-325c418c583e/e6414864-10ec-4040-bd22-e698d8b31790	https://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/eed3c040- d618-42c9-bfcb-325c418c583e/e6414864-10ec-4040-bd22-e698d8b31790/01-701-1015	6
01-701-101	ttps://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/eed3c040- 618-42c9-bfcb-325c418c583e/09ff222c-e45e-43a4-a27b-1f9409474ae8	https://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/eed3c040- d618-42c9-bfcb-325c418c583e/09ff222c-e45e-43a4-a27b-1f9409474ae8/01-701-1015	mmHg
01-701-101	ttps://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/15ece647- 76b-4aa2-b5ad-453bf27c12c1	https://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/15ece647- e76b-4aa2-b5ad-453bf27c12c1/01-701-1015	58.00.0
01-701-101	ttps://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/955c7c7a- ec6-4e79-881a-f73f10360c33	https://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/955c7c7a- aec6-4e79-881a-f73f10360c33/01-701-1015	IN
01-701-101	ttps://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/eed3c040- 618-42c9-bfcb-325c418c583e/86d2e9c9-97a4-4577-a97c-718bd1ecac5a	https://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/eed3c040- d618-42c9-bfcb-325c418c583e/86d2e9c9-97a4-4577-a97c-718bd1ecac5a/01-701-1015	Ę
01-701-101	ttps://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/eed3c040- 618-42c9-bfcb-325c418c583e/a6582ef6-6409-4ce8-8e99-33b656c1492b	https://study.d4k.dk/study-cdisc-pilot-lzzt/fad1b568-92f8-4d89-b470-b37fcb6f4d8d/eed3c040- d618-42c9-bfcb-325c418c583e/a6582ef6-6409-4ce8-8e99-33b656c1492b/01-701-1015	BEATS/MI
01-701-101	ttps://study.d4k.dk/study-cdisc-pilot-lzzt/8877fb52-ea80-4dc8-b99f-341d70c5a796/4b7708f0- eb3-4995-b188-ca426fe5c02e	https://study.d4k.dk/study-cdisc-pilot-lzzt/8877fb52-ea80-4dc8-b99f-341d70c5a796/4b7708f0- 0eb3-4995-b188-ca426fe5c02e/01-701-1015	
01-701-101	ttps://study.d4k.dk/study-cdisc-pilot-lzzt/8877fb52-ea80-4dc8-b99f-341d70c5a796/1b2e1fa0- e5e-4b88-a019-70a29cd50ce7	https://study.d4k.dk/study-cdisc-pilot-lzzt/8877fb52-ea80-4dc8-b99f-341d70c5a796/1b2e1fa0- de5e-4b88-a019-70a29cd50ce7/01-701-1015	U/L
01-701-101	ttps://study.d4k.dk/study-cdisc-pilot-lzzt/e9de10ff-c6c0-45c6-812a-685d20747ce7/4b7708f0- eb3-4995-b188-ca426fe5c02e	https://study.d4k.dk/study-cdisc-pilot-lzzt/e9de10ff-c6c0-45c6-812a-685d20747ce7/4b7708f0- 0eb3-4995-b188-ca426fe5c02e/01-701-1015	

Notes

- •The data loads require a triple of the subject identifier, the data contract URI and the data value
- •This allows for data to be linked into the overall data, in bulk or individually





And so ...

2. Objectives

2.1. Primary Objectives

....

.........

- The primary objectives of this study are
- To determine if there is a statistically significant relationship (overall Type 1 error rate, a: -05) between the change in both ADAS-Cog (see Attachment LZZT 2) and CIBIC+ (see Attachment LZZT-3) scores, and drug dose (0, 50 cm² [54 mg], and 75 cm² [81 mg]).
- To document the safety profile of the xanomeline TTS.

2.2. Secondary Objectives

- The secondary objectives of this study are
- To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas (see Attachment LZZT4).
- To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).
- To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Atzheimer's Disease Assessment Steal-4 vi tern Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).
- To assess the treatment response as a function of Apo E genotype.





Si. 18	bject D	ate				0.0
574	Tabject	BC .	Property	Value		Q Begin typing to search
701	05-205- 3015	Alatine Aminotransferaus Concentration in Serum/Plasma	Laboratory Test Result	-41	https://study.dik.dk/study.cline.cl 0216-450c-6656-bx0100421086/ b07e-c110bladc657/01-701-101	Raw Data
701	01-701- 1015	Alanine Antontanoferase Concentration II Serum/Plasme	Laboratory Test Result	27	Mgac/stady-d48.dk/stady-odae 9299-6899-6473-02750844884/2 9272-67985662537/07-731-1315	Raw Data
701	01-701 1015	Alarine Aninotransferase Concentration in Berum/Plasma	Laboratory Test Result	23	Mpsc/mady-446.dk/mady-chico.pdid-tact-in- d000-413a-91c1-cfb3e50312x8/2222aa374-3849-48a3 b07a-x79856ab/t51701-701-1315	d380-413a-91c1-070ia5021326/2242aa34-3829 46e3107a-e73855e0ctb7
701	01.701	Alanine Aministransferane	Laboratory	17	https://etudy.d4k.dk/etudy.edisc.plint.lest.9877fb52	Prepa Datuda dek dk/studa edise pilot/tas/38778-52











Present Raw Data

Site Subject BC Property Value DataPoint URI DataContract URI 701 01-701- 1015 Alanine Aminotransferase Concentration in Serum/Plasma Laboratory Laboratory Concentration in Serum/Plasma 41 https://study.d4k.dk/study-cdisc-pilot-lzzt/6f26a59c- b07a-e7f8b5a0cfb7/01-701-1015 https://study.d4k.dk/study-cdisc-pilot-lzzt/6f26a59c- b07a-e7f8b5a0cfb7/01-701-1015 https://study.d4k.dk/study-cdisc-pilot-lzzt/6f26a59c- b07a-e7f8b5a0cfb7/01-701-1015 https://study.d4k.dk/study-cdisc-pilot-lzzt/6f26a59c- b07a-e7f8b5a0cfb7 https://study.d4k.dk/study-cdisc-pilot-lzzt/6f26a59c- b07a-e7f8b5a0cfb7 https://study.d4k.dk/study-cdisc-pilot-lzzt/6f26a59c- b07a-e7f8b5a0cfb7 701 01-701- Alanine Aminotransferase Laboratory 27 https://study.d4k.dk/study-cdisc-pilot-lzzt/fa1b568- 92f8-4d89-b470-b37fcb6f4d8d/22d2ea74-38d9-4be3- b07a-e7f8b5a0cfb7 https://study.d4k.dk/study-cdisc-pilot-lzzt/07f7ba56- b07a-e7f8b5a0cfb7 701 01-701- Alanine Aminotransferase Laboratory 23 https://study.d4k.dk/study-cdisc-pilot-lzzt/07f7ba56- https://study.d4k.dk/study-cdisc-pilot-lzzt/07f7ba56-	Property Value DataPoint URI DataContract URI	
1015 Concentration in Serum/Plasma Test Result 8216-40dc-8d86-ba0f0042188b/22d2ea74-38d9-4be3- b07a-e7f8b5a0cfb7/01-701-1015 8216-40dc-8d86-ba0f0042188b/22d2ea74-38d9-4be3- 4be3-b07a-e7f8b5a0cfb7 701 01-701- 1015 Alanine Aminotransferase Concentration in Serum/Plasma Laboratory Test Result 27 27 27 27 27 27 27 27 27 27 27 27 27 2		
1015 Concentration in Serum/Plasma Test Result 92f8-4d89-b470-b37fcb6f4d8d/22d2ea74-38d9-4be3- b07a-e7f8b5a0cfb7/01-701-1015 92f8-4d89-b470-b37fcb6f4d8d/22d2ea b07a-e7f8b5a0cfb7	centration in Test Result 8216-40dc-8d86-ba0f0042188b/22d2ea74-38d9-4be3- 8216-40dc-8d86-ba0f0042	
701 01-701- Alanine Aminotransferase Laboratory 23 https://study.d4k.dk/study-cdisc-pilot-lzzt/0f7dba56- https://study.d4k.dk/study-cdisc-pilot-lzzt/0f7dba56-	centration in Test Result 92f8-4d89-b470-b37fcb6f4d8d/22d2ea74-38d9-4be3- 92f8-4d89-b470-b37fcb6f4	
1015 Concentration in Test Result d380-413a-91c1-cf0da50312c8/22d2ea74-38d9-4be3- d380-413a-91c1-cf0da50312c8/22d2ea Serum/Plasma b07a-e7f8b5a0cfb7/01-701-1015 4be3-b07a-e7f8b5a0cfb7	centration in Test Result d380-413a-91c1-cf0da50312c8/22d2ea74-38d9-4be3- d380-413a-91c1-cf0da503	
701 01-701- Alanine Aminotransferase Laboratory 17 https://study.d4k.dk/study-cdisc-pilot-lzzt/8877fb52- https://study.d4k.dk/study-cdisc-pilot-lzzt/8877fb52-	ine Aminotransferase Laboratory 17 https://study.d4k.dk/study-cdisc-pilot-lzzt/8877fb52- https://study.d4k.dk/study	-cdisc-pilot-lzzt/887



Present SDTM Data



d4k Study Browser STUDIES STATUS

SDTM LB Domain Data

Data queried from the database for the Laboratory Test Results domain

STUDYID DOMAIN USUBJID LBSEQ LBTESTCD LBTEST LBCAT LBSCAT LBSCRES LBORRESU LBRESSCL LBRESTYP LBCOLSRT LBORNRLO LBORNRL

d4k Study B	Browser	STUDIES ST	H2Q-MC- LZZT	LB	01-701- 1015	ALP		34	U/L			
SDTM VS Domain Data		H2Q-MO- LZZT	LB	01-701- 1015	ALP		50	U/L				
Data queries		USUBJID	H2Q-MC- LZZT	LB	01-701- 1015	ALP		41	U/L			
H2Q-MC- LZZT	VS	01-701- 1015	H2Q-MC- LZZT	LB	01-701- 1015	ALP		43	U/L			
H2Q-MC- LZZT	VS	01-701- 1015	H2Q-MC- LZZT	LB	01-701- 1015	ALP		47	U/L			
H2Q-MC- LZZT	VS	01-701- 1015	H2Q-MC-	LB	01-701-	ALP		53	U/L			
H2Q-MC- LZZT	VS	01-701- 1015		ABP		59	mmHg			Screening 2	Screening	PT1M
H2Q-MC- LZZT	VS	01-701- 1015	DI	ABP		71	mmHg			Screening 2	Screening	PT2M
H2Q-MC- LZZT	VS	01-701- 1015	DI	ABP		68	mmHg			Screening 2	Screening	PT5M
H2Q-MC- LZZT	VS	01-701- 1015	DI	ABP		51	mmHg			Baseline	Treatment 1	PT1M
H20-MC	VS	01-701	01	122		51	~ mt *~			Rappling	Treatment	55017

Notes

- Can export the data into SDTM via query
- Derived data is handled
- The solution can handle the "unexpected"
- Think about the data, not how it is presented
- It works in 'real time'



0 💿

Configure Domains



	Biomedical Concepts Linked with VS Domain			
d4k Study Browser studies status	Rows: 10 -	Q Begin typing to sea		
SDTM LB Domain BC Links	Name			
Set set of BCs linked with the SDTM Laboratory Test Res	Diastolic Blood Pressure		\otimes	
Biomedical Concepts Linked with LB Domain	Heart Rate	\otimes		
Rows: 10- Name	Height		\otimes	
Alanine Aminotransferase Concentration in Serum/Plasm	Systolic Blood Pressure	\otimes		
Albumin Presence in Urine	Temperature		\otimes	
Alkaline Phosphatase Concentration in Serum/Plasma	Weight		\otimes	
Aspartate Aminotransferase in Serum/Plasma	(>)			
Creatinine Concentration in Urine	\otimes			
Hemoglobin A1C Concentration in Blood	×			
Potassium Concentration in Urine	\otimes			
Sodium Concentration in Up				

d4k Study Browser STUDIES STATUS

SDTM VS Domain BC Links

Set set of BCs linked with the SDTM Vital Signs Domain

Notes

- Allows for observations to be "assigned" to domains
- Allows for custom domains etc
- Allows for data to be repeated across domains





2024 US CDISC+TMF Interchange | #ClearDataClearImpact



........



cdisc

.....

· · · · · · · · ·

2024 US CDISC+TMF Interchange | #Clear DataClear Impact



Summary

- USDM provides the strong foundation
- We extended USDM ...
 - Established the data contract
 - Linked in the subject data
 - Linked in SDTM
 - Allows for data capture
 - Extracted SDTM, aCRF and define.xml
- And more to come ...



